中肽線上研討會：25 Years Developing GLP-1 Mimetics for Diabetes and Metabolic Diseases-The Future is Still Very Bright

中肽線上研討會預(yù)告

CPC 3rd Webinar: 25 Years Developing GLP-1 Mimetics for Diabetes and Metabolic Diseases-The Future is Still Very Bright

研討會時間：太平洋時間 2021年8月11日，9:00am;

                        北京時間 2021年8月12日，00:00am;

演講主題：25 Years Developing GLP-1 Mimetics for Diabetes and Metabolic Diseases-The Future is Still Very Bright

演講嘉賓：Richard Pittner, PhD；VP of Discovery Biology @Escient Pharmaceuticals

大綱：GLP-1 was identified as the first incretin, released post-prandially to stimulate a decrease in blood glucose levels. Unlike administered insulin or other oral agents, GLP-1 does not cause hypoglycemia. It’s insulin-releasing effect is glucose-dependent, alongside its ability to delay post-prandial glucose excursion – making it a very attractive target for pharmaceutical development. Byetta (Exendin-4), the first potent and long-lasting GLP-1 mimetic, paved the way for demonstrating the therapeutic value of GLP-1 agonism. Since Byetta’s approval in 2005, a number of GLP-1 agonists are now available such as Liraglutide (Victoza) and Dulaglutide (Trulicity), with more favorable efficacy and delivery options. The differentiation requirement is now set very high for the next generation of therapeutics. This presentation will focus on the development of the latest GLP-1 mimetics and GLP-1/GIP dual agonists, namely Semaglutide (Ozempic) and Tirzepatide, with unparalleled efficacy and ease of delivery.

會議注冊鏈接：https://us02web.zoom.us/webinar/register/WN_urDjZI_2QE2uNsHfa7L19A

中肽生化線上論壇，期待您的加入！